glp-1 egfr cut off Updated evidence on cardiovascular and renal effects of receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives | Cardiovascular Diabetology View of Managing hyperglycaemia in

doi: 10.1016/j.bbr.2016.10.033 207 BombaMCiavardelliDSilvestriECanzonieroLMLattanzioRChiappiniPet al

Paulescu published his results the following year and then took out a Romanian patent on his technique in April 1922

The ADA recommends using GLP-1 M for its additional cardiovascular and kidney benefits

The Diabetes Prevention Program demonstrated that intensive lifestyle interventiontargeting 7% weight loss through reduced caloric intake (1200-1800 kcal/day based on initial weight) and 150 minutes weekly of moderate physical activityreduced type 2 diabetes incidence by 58% over three years

JAMA Internal Medicine

This combination supports a steady energy release